Gast ::
| Hauptseite > Publikationsdatenbank > Coffee effectively attenuates impaired attention in ADORA2A C/C-allele carriers during chronic sleep restriction > print |
| Hauptseite > Publikationsdatenbank > Coffee effectively attenuates impaired attention in ADORA2A C/C-allele carriers during chronic sleep restriction > print |
| 001 | 905084 | ||
| 005 | 20230123101844.0 | ||
| 024 | 7 | _ | |a 10.1016/j.pnpbp.2020.110232 |2 doi |
| 024 | 7 | _ | |a 0278-5846 |2 ISSN |
| 024 | 7 | _ | |a 1878-4216 |2 ISSN |
| 024 | 7 | _ | |a 2128/32397 |2 Handle |
| 024 | 7 | _ | |a 33373678 |2 pmid |
| 024 | 7 | _ | |a WOS:000663332600001 |2 WOS |
| 037 | _ | _ | |a FZJ-2022-00383 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Baur, Diego M. |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Coffee effectively attenuates impaired attention in ADORA2A C/C-allele carriers during chronic sleep restriction |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2021 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1667571982_3682 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Many people consume coffee to attenuate increased sleepiness and impaired vigilance and attention due to insufficient sleep. We investigated in genetically caffeine sensitive men and women whether ‘real world’ coffee consumption during a simulated busy work week counteracts disabling consequences of chronically restricted sleep. We subjected homozygous C-allele carriers of ADORA2A (gene encoding adenosine A2A receptors) to five nights of only 5 h time-in-bed. We administered regular coffee (n = 12; 200 mg caffeine at breakfast and 100 mg caffeine after lunch) and decaffeinated coffee (n = 14) in double-blind fashion on all days following sleep restriction. At regular intervals four times each day, participants rated their sleepiness and performed the psychomotor vigilance test, the visual search task, and the visuo-spatial and letter n-back tasks. At bedtime, we quantified caffeine and the major caffeine metabolites paraxanthine, theobromine and theophylline in saliva. The two groups did not differ in age, body-mass-index, sex-ratio, chronotype and mood states. Subjective sleepiness increased in both groups across consecutive sleep restriction days and did not differ. By contrast, regular coffee counteracted the impact of repeated sleep loss on sustained and selective attention, as well as executive control when compared to decaffeinated coffee. The coffee also induced initial or transient benefits on different aspects of baseline performance during insufficient sleep. All differences between the groups disappeared after the recovery night and the cessation of coffee administration. The data suggest that ‘real world’ coffee consumption can efficiently attenuate sleep restriction-induced impairments in vigilance and attention in genetically caffeine sensitive individuals. |
| 536 | _ | _ | |a 5252 - Brain Dysfunction and Plasticity (POF4-525) |0 G:(DE-HGF)POF4-5252 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 650 | 2 | 7 | |a Medicine |0 V:(DE-MLZ)SciArea-190 |2 V:(DE-HGF) |x 0 |
| 650 | 1 | 7 | |a Health and Life |0 V:(DE-MLZ)GC-130-2016 |2 V:(DE-HGF) |x 0 |
| 700 | 1 | _ | |a Lange, Denise |0 P:(DE-Juel1)165827 |b 1 |
| 700 | 1 | _ | |a Elmenhorst, Eva-Maria |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Elmenhorst, David |0 P:(DE-Juel1)131679 |b 3 |
| 700 | 1 | _ | |a Bauer, Andreas |0 P:(DE-Juel1)131672 |b 4 |u fzj |
| 700 | 1 | _ | |a Aeschbach, Daniel |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Landolt, Hans-Peter |0 P:(DE-HGF)0 |b 6 |e Corresponding author |
| 773 | _ | _ | |a 10.1016/j.pnpbp.2020.110232 |g Vol. 109, p. 110232 - |0 PERI:(DE-600)2008803-6 |p 110232 - |t Progress in neuro-psychopharmacology & biological psychiatry |v 109 |y 2021 |x 0278-5846 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/905084/files/1-s2.0-S0278584620305480-main.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:905084 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland |0 I:(DE-HGF)0 |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Sleep & Health Zurich, University Center of Competence, University of Zurich, Zurich, Switzerland |0 I:(DE-HGF)0 |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Sleep and Human Factors, Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany |0 I:(DE-HGF)0 |b 1 |6 P:(DE-Juel1)165827 |
| 910 | 1 | _ | |a Faculty of Medicine, University of Bonn, Bonn, Germany |0 I:(DE-HGF)0 |b 3 |6 P:(DE-Juel1)131679 |
| 910 | 1 | _ | |a Institute of Neuroscience and Medicine, Forschungszentrum Jülich, Jülich, Germany |0 I:(DE-HGF)0 |b 3 |6 P:(DE-Juel1)131679 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)131672 |
| 910 | 1 | _ | |a Faculty of Medicine, University of Bonn, Bonn, Germany |0 I:(DE-HGF)0 |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Sleep and Human Factors, Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany |0 I:(DE-HGF)0 |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland |0 I:(DE-HGF)0 |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Sleep & Health Zurich, University Center of Competence, University of Zurich, Zurich, Switzerland |0 I:(DE-HGF)0 |b 6 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5252 |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-02-04 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PROG NEURO-PSYCHOPH : 2019 |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-02-04 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-04 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-02-04 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-04 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-02-04 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-04 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|